Mr. Will Rascan reports

NOVA MENTIS ANNOUNCES CHANGE OF DIRECTORS AND OFFICERS

Nova Mentis Life Science Corp.'s Dr. Stephen Glazer has resigned as chief scientific officer and a director of the company, effective Dec. 6, 2023. In consideration of the resignation received from Dr. Glazer, he will not stand for re-election at the company's upcoming annual general meeting of shareholders on Dec. 28, 2023.

The board would like to thank Dr. Glazer for his involvement with Nova and wishes him the best in future endeavours.

About Nova Mentis Life Science Corp.

Nova Mentis Life Science is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

We seek Safe Harbor.